LEIDOS BIOMEDICAL RESEARCH, INC.
NEURESTA DRUG SUBSTANCE MANUFACTURING
NEURESTA DRUG SUBSTANCE MANUFACTURING is a funding opportunity from LEIDOS BIOMEDICAL RESEARCH, INC., up to 1363, closing September 2, 2027.
Sep 2, 2027
(398d left)Overview
The overall objective of this SOW is for Leidos to support development of NgR(310)Fc [AXER-204] for treatment of spinal cord injury and produce quantities of hNgR(310)-Fc for use in human clinical studies, in technical and project management, records management, evaluation of quality systems, logistics and chemistry,…